iHuman (IH) Fundamentals 2026 — P/E 1.3x, Revenue Analysis | SniperIQ
iHuman (IH) is a CN-listed Consumer Defensive company in Education & Training Services with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is iHuman's market cap?
iHuman (IH) has a market capitalization of approximately
What is iHuman's P/E ratio?
iHuman's trailing twelve-month P/E ratio is 1.3x, with a price-to-book (P/B) of 0.1x. Valuation multiples are best compared with Consumer Defensive sector peers rather than read in isolation.
How profitable is iHuman?
iHuman runs a net profit margin of 9.4%, a gross margin of 67.5%, and an operating margin of 4.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does iHuman generate?
iHuman reported revenue of ¥807M for fiscal year 2025, with net income of ¥95M and earnings per share (EPS) of 9.1. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does iHuman pay a dividend?
iHuman offers a trailing dividend yield of about 6.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is iHuman financially healthy?
iHuman carries a debt-to-equity ratio of 0.01x and a current ratio of 3.50x, with a market beta of 0.11. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is iHuman a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For iHuman (IH) the key facts are: market cap
Track iHuman's full fundamentals live
Get iHuman's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.